Ipamorelin releases a clean growth-hormone pulse — and the freshest studies are the story this desk leads with.

The short version

Ipamorelin is a small lab-made peptide — five amino acids strung together — that tells the pituitary gland (a small gland under the brain) to release a short burst of growth hormone. Its claim to fame is that it does this cleanly: it raises growth hormone without much of the cortisol (a stress hormone) or prolactin spillover that older peptides cause ^[1]. The newest work is mostly review papers and animal studies. In 2024, ipamorelin cut chemotherapy-driven weight loss in ferrets by about a quarter ^[5]. Earlier human data are thin: one small pharmacology study measured a roughly two-hour half-life ^[2], and the only mid-stage human trial — for slow bowel recovery after surgery — did not beat placebo ^[3]. It is not an approved medicine anywhere. What people report — including the downsides like flushing and water retention — is laid out on the effects page.

What the newest ipamorelin studies actually found

The freshest published ipamorelin study is a 2024 ferret experiment. Intraperitoneal ipamorelin at 1–3 mg/kg inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48–72 h), with no anti-emetic effect — the weight benefit came through a peripheral route, not by stopping nausea ^[5]. That is the most recent in-vivo data point, and it lands ipamorelin squarely in the cachexia (disease-driven wasting) conversation rather than the muscle-building one.

The 2026 review literature is consistent about where the field stands. An orthopaedic and sports-medicine narrative review reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension (peak muscle force) in a glucocorticoid-induced muscle-loss model in mice — while stressing the evidence is limited to animals ^[14]. Separate 2026 reviews in sports medicine ^[15][17] and a broad therapeutic-peptide review ^[16] reach the same verdict: a promising mechanism, real preclinical signals, and an absence of rigorous human trials. The recent-research lens does not soften that — it sharpens it.

Selectivity is the finding that made ipamorelin

Ipamorelin's founding 1998 characterization is still its defining result. In primary rat pituitary cells, anaesthetised rats, and conscious swine, it released growth hormone potently (swine ED50 = 2.3 nmol/kg, against 3.9 nmol/kg for GHRP-6) — yet it did not raise ACTH (the hormone that drives cortisol) or cortisol above the level seen with GHRH, even at doses more than 200-fold above its growth-hormone ED50 ^[1]. That selectivity — strong growth-hormone release, minimal stress-hormone spillover — is what separated it from earlier growth-hormone-releasing peptides and is the property every later study is read against.

The mechanism is specific. Ipamorelin binds GHS-R1a (the ghrelin receptor, the same receptor the body's natural 'hunger hormone' uses) on pituitary cells and triggers a calcium-driven pulse of growth hormone ^[1]. Because it works through a different door than GHRH analogs, it is mechanistically complementary to them — which is the entire rationale behind pairing it with a GHRH analog. The mechanism, drawn out plainly, lives on how ipamorelin works.

The human data is small, and one trial is the anchor

Two human datasets carry most of the weight. A 1999 pharmacokinetic study in eight healthy male volunteers per dose level (five 15-minute IV infusions, 4.21–140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of about 2 hours, and a single growth-hormone pulse peaking around 40 minutes after dosing ^[2]. That is precise, and it is most of what is known about how ipamorelin behaves in a human body.

The efficacy anchor is less flattering. The only published Phase 2 randomized controlled trial (NCT00672074; 114 adults after bowel resection, 0.03 mg/kg IV twice daily for up to 7 days) missed its primary endpoint: median time to first tolerated meal was 25.3 h with ipamorelin versus 32.6 h with placebo (p = 0.15) ^[3]. No ipamorelin-specific safety signal appeared in that short window, but efficacy was not demonstrated, and no Phase 3 followed. A data-forward read states both halves: the pharmacology is clean; the one controlled human outcome trial was negative.

Where this desk points next

Three reads tie the site together. The research page walks the mechanism and every study by tissue. The effects page covers what people in research-use communities report — benefits and downsides, clearly labeled anecdotal — plus the cited safety cautions. And the references list carries every DOI and PubMed link. Two questions drive most searches here, and both get dedicated pages: ipamorelin benefits, and what does ipamorelin peptide do.